Kamyar Kalantar-Zadeh M.D. to Cholesterol, HDL
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Cholesterol, HDL.
Connection Strength
2.269
-
Association of serum lipids with outcomes in Hispanic hemodialysis patients of the West versus East Coasts of the United States. Am J Nephrol. 2015; 41(4-5):284-95.
Score: 0.475
-
Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol Dial Transplant. 2014 Aug; 29(8):1554-62.
Score: 0.436
-
Role of HDL dysfunction in end-stage renal disease: a double-edged sword. J Ren Nutr. 2013 May; 23(3):203-6.
Score: 0.412
-
Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2011 Dec; 6(12):2861-70.
Score: 0.371
-
Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients. J Clin Lipidol. 2018 Mar - Apr; 12(2):488-497.
Score: 0.143
-
Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clin J Am Soc Nephrol. 2017 Apr 03; 12(4):591-602.
Score: 0.134
-
Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. Am J Kidney Dis. 2015 Aug; 66(2):313-21.
Score: 0.117
-
A matched comparison of serum lipids between hemodialysis patients and nondialysis morbid controls. Hemodial Int. 2005 Jul; 9(3):314-24.
Score: 0.060
-
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2020 04 28; 323(16):1565-1573.
Score: 0.042
-
Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients. J Clin Endocrinol Metab. 2019 10 01; 104(10):4848-4856.
Score: 0.040
-
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 11; 217:72-83.
Score: 0.040